Mobileye Achieves 99.6% Fewer Losses Despite Only Slight Increase in Revenue

Inc., a prominent player in autonomous vehicle technology, saw its Q3 2025 revenue grow by $18 million, attributed to inventory adjustments among Tier 1 suppliers. The company reported an operating loss of $109 million, a substantial recovery compared to the $2.8 billion loss recorded in the prior year’s third quarter. Gross profit increased to $243 million, reflecting improved cost controls, as detailed in its . Revenue contributions from the U.S., China, and Germany were $111 million, $118 million, and $77 million, respectively, highlighting the company’s international market dependence.

In other news, Mohawk Industries Inc. released its

, and scheduled a conference call for October 24 to address challenges such as inflation, tariffs, and global instability. The company cautioned that fluctuations in shipping and raw material expenses could affect upcoming profits. They also highlighted the use of non-GAAP metrics, providing reconciliations for clarity.

Within the biotech industry, Avidity Biosciences, Inc. is subject to a 46-day

on certain options, preventing company leaders from selling shares until October 27, 2025. This restriction, enforced by underwriters Leerink Partners and J.P. Morgan, is intended to help maintain stock stability following the offering.

Yuanbao Inc., a fintech company based in China, is under a

for its ordinary shares, restricting sales until October 27, 2025. This measure applies to executives, board members, and current shareholders, following standard post-IPO protocols to discourage market manipulation.

Akbank TAS (AKBTY) discussed ongoing economic headwinds during its

, noting that its 25% return on equity target may be threatened by slower-than-expected rate reductions. Management anticipates the policy rate will reach 38% by year’s end, which could compress net interest margins. Nevertheless, fee income continues to grow, supported by new customer acquisition and regulatory changes.

WuXi AppTec, a leading Chinese pharmaceutical services provider, achieved double-digit revenue growth from Q1 to Q3 2025 and

to 17-18%, up from the previous 13-17% range. The company’s backlog for ongoing projects climbed to RMB59.9 billion, indicating robust demand for its CRDMO offerings. Free cash flow is now forecasted at RMB8.0-8.5 billion, up from RMB5.0-6.0 billion, thanks to operational efficiencies and project completions.

Clean Energy, a company specializing in renewable fuels,

, fueled by the sale of 61.4 million gallons of RNG. Although a GAAP net loss of $217-$212 million is projected for 2025, adjusted EBITDA is expected to reach between $60 and $65 million. The company faces obstacles such as asset depreciation and Amazon warrant expenses, but leadership remains confident in sustained long-term expansion.